Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a report released on Tuesday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Price Performance

Shares of NASDAQ:TTNP opened at $7.21 on Tuesday. The company has a market capitalization of $6.59 million, a price-to-earnings ratio of -0.88 and a beta of 1.33. The business’s 50-day moving average is $7.34 and its 200-day moving average is $7.17. Titan Pharmaceuticals has a 1 year low of $5.00 and a 1 year high of $16.60.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union.